Featured Research

from universities, journals, and other organizations

Experimental drug reduces brain damage, eliminates brain hemorrhaging in rodents afflicted by stroke

Date:
October 25, 2013
Source:
University of Southern California - Health Sciences
Summary:
The experimental drug 3K3A-APC shows promise as a stand-alone therapy for stroke or in combination with the FDA-approved clot-busting drug therapy tPA (tissue plasminogen activator).

An experimental drug called 3K3A-APC appears to reduce brain damage, eliminate brain hemorrhaging and improve motor skills in older stroke-afflicted mice and stroke-afflicted rats with comorbid conditions such as hypertension, according to a new study from Keck Medicine of USC.

The study, which appears online today in the journal Stroke, provides additional evidence that 3K3A-APC may be used as a therapy for stroke in humans, either alone or in combination with the FDA-approved clot-busting drug therapy tPA (tissue plasminogen activator). Clinical trials to test the drug's efficacy in people experiencing acute ischemic stroke are expected to begin recruiting patients in the U.S. in 2014.

"Currently, tPA is the best treatment for stroke caused by a blocked artery, but it must be administered within three hours after stroke onset to be effective," said Berislav V. Zlokovic, MD, PhD, director of the Zilkha Neurogenetic Institute (ZNI) at the Keck School of Medicine of USC and the study's lead investigator. "Because of this limited window, only a small fraction of those who suffer a stroke reach the hospital in time to be considered for tPA. Our studies show that 3K3A-APC extends tPA's therapeutic window and counteracts tPA's tendency to induce bleeding in the brains of animals having a stroke."

Zlokovic is the scientific founder of ZZ Biotech, a Houston-based biotechnology company he co-founded with USC benefactor Selim Zilkha to develop biological treatments for stroke and other neurological ailments. ZZ Biotech's 3K3A-APC is a genetically engineered variant of the naturally occurring activated protein C (APC), which plays a role in the regulation of blood clotting and inflammation. 3K3A-APC has been shown to have a protective effect on the lining of blood vessels in rodent brains, which appears to help prevent bleeding caused by tPA.

In collaboration with Cedars-Sinai Medical Center and The Scripps Research Institute, Zlokovic and his team gave tPA -- alone and in combination with 3K3A-APC -- to mature female mice and male hypertensive rats four hours after stroke. They also gave 3K3A-APC in regular intervals up to seven days after stroke. They measured the amount of brain damage, bleeding and motor ability of the rodents up to four weeks after stroke.

The researchers found that, under those conditions, tPA therapy alone caused bleeding in the brain and did not reduce brain damage or improve motor ability when compared to the control. The combination of tPA and 3K3A-APC, however, reduced brain damage by more than half, eliminated tPA-induced bleeding and significantly improved motor ability.

"Scientists all around the globe are studying potential stroke therapies, but very few have the robust preclinical data package that 3K3A-APC has," said Kent Pryor, PhD, MBA, ZZ Biotech's chief operating officer. "The results from Dr. Zlokovic's studies have been very promising."

Zlokovic's team previously reported similar results in young, healthy male rodents. A Phase 1 trial testing the safety of 3K3A-APC in healthy human volunteers, led by study co-author Patrick D. Lyden, M.D., of Cedars-Sinai, concluded in February.

"We now have opened an investigational new drug application at the FDA to conduct a Phase 2 clinical trial of 3K3A-APC in patients experiencing acute ischemic stroke," said Joe Romano, CEO and president of ZZ Biotech. "We are excited to see 3K3A-APC move from healthy volunteers to real patients suffering from this terrible disease."


Story Source:

The above story is based on materials provided by University of Southern California - Health Sciences. Note: Materials may be edited for content and length.


Journal Reference:

  1. Wang, Y., Zhao, Z., Chow, N., Rajput, P.S., Griffin, J.H., Lyden, P.D. & Zlokovic, B.V. An activated protein C analog protects from ischemic stroke and extends the therapeutic window of tPA in aged female mice and hypertensive rats. Stroke, October 2013

Cite This Page:

University of Southern California - Health Sciences. "Experimental drug reduces brain damage, eliminates brain hemorrhaging in rodents afflicted by stroke." ScienceDaily. ScienceDaily, 25 October 2013. <www.sciencedaily.com/releases/2013/10/131025091951.htm>.
University of Southern California - Health Sciences. (2013, October 25). Experimental drug reduces brain damage, eliminates brain hemorrhaging in rodents afflicted by stroke. ScienceDaily. Retrieved August 20, 2014 from www.sciencedaily.com/releases/2013/10/131025091951.htm
University of Southern California - Health Sciences. "Experimental drug reduces brain damage, eliminates brain hemorrhaging in rodents afflicted by stroke." ScienceDaily. www.sciencedaily.com/releases/2013/10/131025091951.htm (accessed August 20, 2014).

Share This




More Mind & Brain News

Wednesday, August 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Charter Schools Alter Post-Katrina Landscape

Charter Schools Alter Post-Katrina Landscape

AP (Aug. 20, 2014) Nine years after Hurricane Katrina, charter schools are the new reality of public education in New Orleans. The state of Louisiana took over most of the city's public schools after the killer storm in 2005. (Aug. 20) Video provided by AP
Powered by NewsLook.com
Researcher Testing on-Field Concussion Scanners

Researcher Testing on-Field Concussion Scanners

AP (Aug. 19, 2014) Four Texas high school football programs are trying out an experimental system designed to diagnose concussions on the field. The technology is in response to growing concern over head trauma in America's most watched sport. (Aug. 19) Video provided by AP
Powered by NewsLook.com
Kids' Drawings At Age 4 Linked To Intelligence At Age 14

Kids' Drawings At Age 4 Linked To Intelligence At Age 14

Newsy (Aug. 19, 2014) A study by King's College London says there's a link between how well kids draw at age 4 and how intelligent they are later in life. Video provided by Newsy
Powered by NewsLook.com
Mental, Neurological Disabilities Up 21% Among Kids

Mental, Neurological Disabilities Up 21% Among Kids

Newsy (Aug. 18, 2014) New numbers show a decade's worth of changes in the number of kids with disabilities. They suggest mental disabilities are up; physical ones are down. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins